RT @IHSMarkit: "If you want to take care of shareholders, you better take care of your people, and you better take care of your planet, and…
Pharma's key drivers for 2014
In many ways, 2014 has kicked off in a very similar way to how 2013 started for the global pharmaceutical industry: with a major setback. In 2013, this came at the hands of the unexpected FDA non-approval of Novo Nordisk's new diabetes treatment Tresiba (insulin degludec) in the United States.
In 2014, the bad news came from Germany, where IQWiG's concluded that a trio of innovative treatments - Tafinlar (dabrafenib), Eylea (aflibercept) and Aubagio (terfilunomide) - provided no additional benefits in their respective health technology assessments (HTA). And even while reimbursement issues, drug shortages, and policy reforms continue to change and shape the industry it looks like 2014 may well be a road to economic recovery.
IHS Healthcare and Pharma offers a look at the trends and developments that will shape the industry in 2014.
Key drivers for 2014 1. The foundations for economic recovery continue to be in place 2. The United States' first full year of ACA 3. Europe/Eurozone instability will continue to suppress public health expenditure 4. Secondary emerging markets are expanding healthcare insurance 5. Reimbursement continues to offer a mixed picture 6. Patent expirations continue to be a significant driver, but it is a comparatively quiet year 7. IRP baskets continue to evolve 8. Drug shortages will continue, but clampdowns on parallel exports are seen in many countries 9. Price cuts in Japan - but some incentives for innovation 10. New technology developments
Click here to download more details about what to expect in 2014. We will dive deeply into a number of these ideas in the coming months here on the blog.
- The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September
- Is the US ready to start relaxing COVID-19 lockdowns?
- COVID-19 could cause delays for price framework agreements in parts of Europe
- US scrambles for resources in COVID-19 response
- COVID-19: Risk of severe complications among the United States health workforce
- COVID-19 pandemic: Health system surge capacity
- UK bans parallel export of two COVID-19 treatment candidates to protect national supply
- China’s young biosimilars sector
The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September https://t.co/9fX4R1K8rC